Pneumococcal Disease - Pipeline Insight, 2024

This “Pneumonia, Pneumococcal - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Pneumonia, Pneumococcal pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Pneumonia, Pneumococcal Understanding

Pneumonia, Pneumococcal: Overview

Pneumonia, Pneumococcal is an infection caused by the bacteria Streptococcus pneumoniae or pneumococcus. Disease is most common at the extremes of age, i.e, in young children and among the elderly. There are two main types of Pneumonia, Pneumococcal: non invasive and invasive with noninvasive being the less serious. Non Invasive Pneumonia, Pneumococcal: it occurs outside the major organs of the blood and the bacteria can cause- Bronchitis, Sinusitis. Invasive Pneumonia, Pneumococcals: Invasive Pneumonia, Pneumococcals (IPDs) are more serious than the noninvasive type and occur inside a major organ or in a person’s blood and the bacteria can cause: Pneumonia, Meningitis and sepsis. S. pneumoniae bacteria are common in the throat and nose. Bacteria can spread through droplets in the air and do not spread through contaminated food or water.

Pneumonia, Pneumococcal - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pneumonia, Pneumococcal pipeline landscape is provided which includes the disease overview and Pneumonia, Pneumococcal treatment guidelines. The assessment part of the report embraces, in depth Pneumonia, Pneumococcal commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pneumonia, Pneumococcal collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Pneumonia, Pneumococcal R&D. The therapies under development are focused on novel approaches to treat/improve Pneumonia, Pneumococcal.

Pneumonia, Pneumococcal Emerging Drugs Chapters

This segment of the Pneumonia, Pneumococcal report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pneumonia, Pneumococcal Emerging Drugs

20 Valent Pneumococcal conjugate vaccine (20vPnC): Pfizer Pfizer’s 20vPnC vaccine candidate includes capsular polysaccharide conjugates for the 13 serotypes already included in Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine[Diphtheria CRM197 Protein]). The vaccine also contains capsular polysaccharide conjugates for seven additional serotypes that cause invasive Pneumonia, Pneumococcal. U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for 20vPnC for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in the vaccine candidate in adults age 18 years or older. If approved, 20vPnC will cover more serotypes responsible for the majority of Pneumonia, Pneumococcal than any other pneumococcal conjugate vaccine currently licensed or currently in late-stage clinical development. Importantly, 20vPnC has shown to induce immune memory, which provides protection and efficacy against non-bacteremic pneumonia, particularly in olderadults.

ASP3772: Affinivax ASP3772 utilizes the Multiple Antigen Presenting System (MAPS) platform which is Affinivax’s proprietary, next-generation vaccine technology. MAPS vaccine can present both the polysaccharide and the protein antigens to the host immune system to induce both a B- and T-cell immune response. ASP3772 is a vaccine candidate that offers the potential to provide broader protection against Pneumonia, Pneumococcal. It is currently in phase II stage of development by Affinivax partnership with Astellas Pharma Inc., includes 24 pneumococcalserotypes.

Pneumonia, Pneumococcal: Therapeutic Assessment

This segment of the report provides insights about the different Pneumonia, Pneumococcal drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Pneumonia, Pneumococcal

There are approx. 5+ key companies which are developing the therapies for Pneumonia, Pneumococcal. The companies which have their Pneumonia, Pneumococcal drug candidates in the most advanced stage, i.e. pre-registration include, Pfizer.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II and Phase I/II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

The Pneumonia, Pneumococcal pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Peptides
• Vaccines
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pneumonia, Pneumococcal: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pneumonia, Pneumococcal therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pneumonia, Pneumococcal drugs.

Pneumonia, Pneumococcal Report Insights

• Pneumonia, Pneumococcal Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Pneumonia, Pneumococcal Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Pneumonia, Pneumococcal drugs?
• How many Pneumonia, Pneumococcal drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pneumonia, Pneumococcal?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pneumonia, Pneumococcal therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Pneumonia, Pneumococcal and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Pfizer
• Affinivax
• Merck Sharp &Dohme Corp.
• Vaxcyte
• SK Chemicals

Key Products

• 20vPnC
• V114
• ASP3772
• VAX-A1
• Pneumococcal vaccine conjugate